Indoor Tanning Addiction: Biological Mechanisms and Association with Other Disorders.

Although many people who use tanning beds are aware of the negative consequences, they continue to indoor tan, possibly due to addictive properties. The purpose of this paper is to review the existing literature on tanning addiction, its potential biological mechanisms, and its association with psychological disorders. A PubMed search was conducted using the terms "Tanning Addiction," "UVR AND B-endorphin," and "tanning dependence AND gene.

Long-term real-world evidence of SB5 (adalimumab biosimilar) treatment in patients with moderate-to-severe psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).

Background: SB5 (adalimumab-bwwd) is an adalimumab biosimilar targeting tumor necrosis factor (TNF) for the treatment of chronic inflammatory diseases, including moderate-to-severe chronic plaque psoriasis.

Objectives: To assess the four-year persistence associated with the effectiveness and safety of SB5 in patients with psoriasis in the UK and Ireland.

Methods: This prospective study included 1195 SB5-treated patients using British Association of Dermatologists' Biologic Interventions Register (BADBIR) between 01 June 2018 and 31 August 2022.

Bimekizumab-bkzx for the Treatment of Plaque Psoriasis: A Drug Review.

Background: Bimekizumab is a biologic targeting interleukin (IL)-17A/17F, approved by the Food and Drug Administration (FDA) for moderate-to-severe plaque psoriasis in 2023.

Data Sources: A PubMed search was performed using the keywords "bimekizumab," "plaque psoriasis," and "bimekizumab clinical trials," from origin to August 1, 2024. We included phase I to III trials of bimekizumab for plaque psoriasis, studies published post-FDA approval, and information from the package insert.

The Influence of Psoriasis on Type 2 Diabetes Mellitus Patient Profiles: A National Inpatient Sample Study.

Background: Psoriasis is believed to be a common comorbidity of type 2 diabetes mellitus (T2DM). Little is known on the impact psoriasis has on T2DM patients' disease profiles.

Objective: To assess the impact psoriasis has on T2DM patients' demographics, comorbidities, and health care outcomes.

Analyzing the Benefits and Costs of the Safe Step Act on Patients, Physicians, and Insurers.

Pharmaceutical expenditures in the United States, particularly in dermatology, have grown rapidly, driven by expensive topical and biologic treatments. Insurers are employing cost-containing strategies such as step therapy, which mandates the use of lower-cost treatments before more expensive medications. The bipartisan Safe Step Act aims to enhance step therapy policies by introducing a transparent process for requesting exceptions and reasonable timelines for the process.

How can physicians improve medication adherence and outcomes in dermatological conditions?

Introduction: Medication non-adherence is a major contributor to suboptimal disease treatment across medical specialties and is a particular hurdle with topicals. While adherence is a patient behavior affected by many socioeconomic and health system factors, physicians can play an important role in encouraging good adherence.

Areas Covered: We discuss methods for measuring adherence, including ethics of such research, provide select examples of dermatology-specific adherence studies, and conclude with physician-focused practices to improve patients' adherence.

Evaluation of ruxolitinib cream 1.5% as an at-home therapy for repigmentation in non-segmental vitiligo.

Introduction: Vitiligo is a chronic, autoimmune condition characterized by skin depigmentation caused by inflammatory-mediated melanocyte degradation. Treatment of vitiligo is challenging due to the chronic nature of the condition. Ruxolitinib cream 1.